药物之间的相互作用1329045个记录(本栏目收费,不能展示细节,电话13136136841)
药物之间的相互作用
Lithium cation
Barbital
The risk or severity of adverse effects can be increased when Somatostatin is combined with Barbital.
Lithium cation
(S)-Warfarin
The serum concentration of (S)-Warfarin can be increased when it is combined with Somatostatin.
Lithium cation
S,R-Warfarin alcohol
The serum concentration of S,R-Warfarin alcohol can be increased when it is combined with Somatostatin.
Lithium cation
R,S-Warfarin alcohol
The serum concentration of R,S-Warfarin alcohol can be increased when it is combined with Somatostatin.
Lithium cation
(R)-warfarin
The serum concentration of (R)-warfarin can be increased when it is combined with Somatostatin.
Lithium cation
Tofacitinib
The metabolism of Tofacitinib can be decreased when combined with Somatostatin.
Lithium cation
Iloperidone
The metabolism of Iloperidone can be decreased when combined with Somatostatin.
Lithium cation
Ibrutinib
The metabolism of Ibrutinib can be decreased when combined with Somatostatin.
Hexobarbital
Satralizumab
The serum concentration of Nintedanib can be decreased when it is combined with Satralizumab.
Hexobarbital
Abametapir
The serum concentration of Nintedanib can be increased when it is combined with Abametapir.
Hexobarbital
Tucatinib
Nintedanib may decrease the excretion rate of Tucatinib which could result in a higher serum level.
Hexobarbital
Cenobamate
The serum concentration of Nintedanib can be decreased when it is combined with Cenobamate.
Hexobarbital
Lasmiditan
The serum concentration of Nintedanib can be increased when it is combined with Lasmiditan.
Hexobarbital
Reviparin
The risk or severity of bleeding can be increased when Reviparin is combined with Nintedanib.
Hexobarbital
Troxerutin
The risk or severity of bleeding can be increased when Nintedanib is combined with Troxerutin.
Hexobarbital
Protocatechualdehyde
The risk or severity of bleeding can be increased when Nintedanib is combined with Protocatechualdehyde.
Hexobarbital
Dabigatran
The risk or severity of bleeding can be increased when Dabigatran is combined with Nintedanib.
Hexobarbital
Edetate calcium disodium anhydrous
The risk or severity of bleeding can be increased when Edetate calcium disodium anhydrous is combined with Nintedanib.
Hexobarbital
Tocopherylquinone
The risk or severity of bleeding can be increased when Tocopherylquinone is combined with Nintedanib.
Hexobarbital
(S)-Warfarin
The risk or severity of bleeding can be increased when (S)-Warfarin is combined with Nintedanib.